Low-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis IP Kosmas, K Zikopoulos, I Georgiou, E Paraskevaidis, C Blockeel, H Tournaye, J Van der Elst, P Devroey Reproductive BioMedicine Online Volume 19, Issue 5, Pages 619-630 (November 2009) DOI: 10.1016/j.rbmo.2009.09.007 Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 1 Flow diagram for meta-analysis: abstract identification and selection. HCG=human chorionic gonadotrophin; RCT=randomized controlled trial. Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 2 Comparison of low-dose human chorionic gonadotrophin (HCG) supplemented antagonist cycles versus non-supplemented cycles and the odds for clinical pregnancy. CI=confidence interval; OR=odds ratio. Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 3 Comparison of low-dose human chorionic gonadotrophin (HCG) supplemented antagonist cycles versus non-supplemented long agonist cycles and the odds for the incidence ovarian hyperstimulation syndrome. CI=confidence interval; OR=odds ratio. Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 4 Comparison of studies with major replacement of low-dose human chorionic gonadotrophin (HCG) supplemented cycles versus non-supplemented cycles and the odds for clinical pregnancy. Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 5 Decision tree and protocol choice. Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 6 Cost effectiveness analysis for the different protocols. Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 7 One-way sensitivity analysis of net monetary benefits (NMB). Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions
Figure 8 Two-way sensitivity analysis of net monetary benefits (NMB). Reproductive BioMedicine Online 2009 19, 619-630DOI: (10.1016/j.rbmo.2009.09.007) Copyright © 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK Terms and Conditions